NLRP3 and COVID-19: While previous studies suggest that DA can supress NLRP3, leucine-rich repeat (LRR), and pyrin domain-containing protein 3 (NLRP3) inflammasome activation via DRD1 pathways (Yan et al., 2015; Wang et al., 2018), our findings indicate that DRD4 may not mediate this mechanism in the context of post-COVID-19 recovery.